Despite the advancement of science and technology, there still remains a huge unmet area of needs in medicine. Patients are still suffering around the world because of the limited therapeutics and patient options available.

While there may be hundreds of biopharmaceutical companies out there, not all are interested to venture into the formulation and development of novelty drugs for these debilitating and often life-threatening diseases. This could be because of the very small market, and the number of patients who could afford the treatment. Nonetheless, Retrophin, Inc. has taken on the challenge of bringing hope to those patients. The company focuses on the development and commercialization of these drugs. Their product candidates are intended to cure glomerulosclerosis, duchenne muscular dystrophy and cerebrotendinous xanthomatosis. Their products are also being studied and tested as possible treatments for other conditions.

Retrophin holds its headquarters in New York and trades its common stocks on the NASDAQ, under the ticker symbol RTRX.